B of A Securities Upgrades Ionis Pharmaceuticals to Neutral, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Neutral and raised the price target from $33 to $52.

October 23, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has been upgraded from Underperform to Neutral by B of A Securities, with a raised price target from $33 to $52.
The upgrade from Underperform to Neutral indicates a more positive outlook on the company by the analyst. The significant increase in the price target from $33 to $52 suggests that the analyst believes the stock is undervalued at its current price. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100